Commercial

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

For In Vivo's 17th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.

The US market’s largest imaging manufacturer marked two years as an independent company with plans to invest in more M&A and PDx production capacity, but reported a modest 2025 revenues outlook.

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

The Swiss major may have to pay over $3bn for the dual-acting Factor XI/XIa inhibitor that it originally developed before the drug was passed on to Anthos Therapeutics, founded by private equity firm Blackstone and the Swiss major in 2019.

Relmada has acquired sepranolone, a potential blockbuster for the complex neurological condition characterized by involuntary tics, for a bargain €3m from the Stockholm group that went into liquidation late last year.

Any tariff headwinds should be counterbalanced by currency tailwinds, predicts German imaging and diagnostics company Siemens Healthineers.

AstraZeneca CEO Pascal Soriot said it was “fake news” to describe the UK as the worst place in the western world for pharma companies to invest and blamed the decision to pull plans for a new £450m vaccines facility near Liverpool on it simply not being economically viable without more government support.

In September last year, J&J lost a court case surrounding its 2019 purchase of Auris health, and was ordered to pay over $1bn in damages. Reactions to the potentially precedent-setting news were harsh and quick. In Vivo spoke to legal, M&A and BD experts from across the medtech industry to learn more about the true impacts.

Now that one of the most controversial pharma M&As of 2024 has closed, did overtures to concerned customers and extended prenotification discussions help Novo and Catalent seal the deal?